Would you consider starting an ACE inhibitor on a patient without CVD or heart failure prior to initiation of anthracyclines to reduce the overall risk of myocardial toxicity?
Answer from: at Academic Institution
Even though the patient does not have CVD or heart failure history, there are still factors to consider if they are at higher risk for anthracycline cardiac toxicity: Lower EF at baseline, significant valvular heart disease, prehypertension/hypertension, diabetes, obesity, advanced age, any subclini...
Sign in or Register to read more
Answer from: at Academic Institution
Based on recent data presented at ACC.23/WCC I would probably initiate statin Rx (STOP CA trial).
In the absence of HTN, DM, CAD and normal baseline LVEF, I don’t think there is a role for routine ACEi/carvedilol use.